WO2023036054A3 - Composition and method for treating hemophilia - Google Patents
Composition and method for treating hemophilia Download PDFInfo
- Publication number
- WO2023036054A3 WO2023036054A3 PCT/CN2022/116702 CN2022116702W WO2023036054A3 WO 2023036054 A3 WO2023036054 A3 WO 2023036054A3 CN 2022116702 W CN2022116702 W CN 2022116702W WO 2023036054 A3 WO2023036054 A3 WO 2023036054A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- treating hemophilia
- hemophilia
- treating
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a method for treating hemophilia A the compositions and the use of compositions for the treatment of hemophilia A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/117166 | 2021-09-08 | ||
| CN2021117166 | 2021-09-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023036054A2 WO2023036054A2 (en) | 2023-03-16 |
| WO2023036054A3 true WO2023036054A3 (en) | 2023-05-11 |
Family
ID=83996714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/116702 WO2023036054A2 (en) | 2021-09-08 | 2022-09-02 | Composition and method for treating hemophilia |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023036054A2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150071883A1 (en) * | 2013-09-12 | 2015-03-12 | Biomarin Pharmaceutical Inc. | Adeno-Associated Virus Factor VIII Vectors |
| WO2017075619A1 (en) * | 2015-10-30 | 2017-05-04 | Spark Therapeutics, Inc. | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders |
| WO2021084275A1 (en) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii polypeptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
-
2022
- 2022-09-02 WO PCT/CN2022/116702 patent/WO2023036054A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150071883A1 (en) * | 2013-09-12 | 2015-03-12 | Biomarin Pharmaceutical Inc. | Adeno-Associated Virus Factor VIII Vectors |
| WO2017075619A1 (en) * | 2015-10-30 | 2017-05-04 | Spark Therapeutics, Inc. | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders |
| WO2021084275A1 (en) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii polypeptide |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE Geneseq [online] 24 June 2021 (2021-06-24), "Human truncated FVIII encoding DNA, SEQ ID 34.", XP093018440, retrieved from EBI accession no. GSN:BJH67048 Database accession no. BJH67048 * |
| DATABASE Geneseq [online] 7 May 2015 (2015-05-07), "Proto 1 vector DNA sequence, SEQ ID 1.", XP093018425, retrieved from EBI accession no. GSN:BBV62965 Database accession no. BBV62965 * |
| JOHN J TOOLE ET AL: "A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity", PROC NATL ACAD SCI USA, vol. 83, no. 16, 1 August 1986 (1986-08-01), pages 5939 - 5942, XP055292120, DOI: 10.1073/pnas.83.16.5939 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023036054A2 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| PH12022553235A1 (en) | Compound for the treatment of coronaviral infections | |
| WO2019224790A3 (en) | Prodrugs of fulvestrant | |
| AU2020258568A8 (en) | CD73 inhibitors | |
| IL308221A (en) | Compositions and methods for the treatment of depression | |
| EP4225923A4 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| WO2021158635A8 (en) | Anti-viral compositions and methods of use | |
| EP4166156A4 (en) | Composition for preventing, ameliorating, or treating allergic diseases or pruritus, containing pentapeptide as active ingredient | |
| EP4096653A4 (en) | Compositions for the treatment of angiolipoma | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant | |
| WO2023285654A3 (en) | Compounds for the treatment of covid-19 | |
| WO2023036054A3 (en) | Composition and method for treating hemophilia | |
| WO2022118016A3 (en) | Enzyme inhibitors | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors | |
| WO2021226439A3 (en) | Engineered relaxins and methods of use thereof | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2024002372A (en) | Herbicidal malonamides. | |
| MX2024006105A (en) | Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma. | |
| CR20230222A (en) | Herbicidal malonamides | |
| CR20230221A (en) | Herbicidal malonamides | |
| MX2022016179A (en) | Compounds and methods for treating fungal infections. | |
| WO2025030142A3 (en) | Methods of treatment using oxytocin | |
| WO2020194296A3 (en) | Compounds, compositions and methods for treating a neurological condition | |
| WO2025049923A3 (en) | Novel treatments of ciliopathies | |
| WO2023034914A3 (en) | Methods for the prevention and treatment of synucleinopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22797003 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22797003 Country of ref document: EP Kind code of ref document: A2 |